<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="363156">
  <stage>Registered</stage>
  <submitdate>15/10/2012</submitdate>
  <approvaldate>18/10/2012</approvaldate>
  <actrnumber>ACTRN12612001115820</actrnumber>
  <trial_identification>
    <studytitle>A Multi-Centre Study to Test the Safety and Performance of the DePuy AVN Cage in Treating Osteonecrosis of the Hip</studytitle>
    <scientifictitle>A Prospective, Single-arm, Uncontrolled, Multi-centre Study to Evaluate the Safety and Efficacy of the DePuy AVN Cage Prosthesis for the Treatment of Avascular Necrosis of the Hip.</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Avascular Necrosis of the Hip</healthcondition>
    <conditioncode>
      <conditioncode1>Musculoskeletal</conditioncode1>
      <conditioncode2>Other muscular and skeletal disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Surgery</conditioncode1>
      <conditioncode2>Other surgery</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>AVN Cage Prosthesis - a metal cage that is inserted into the femoral head and is then packed with bone graft material. Skin to skin time is approximately 45 minutes and the prosthesis is intended to remain in situ permanently.</interventions>
    <comparator>Not applicable</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: surgery</interventioncode>
    <interventioncode>Treatment: Devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Lack of disease progression as measured by x-rays, CT &amp; MRI</outcome>
      <timepoint>2 years</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>No requirement for further surgery</outcome>
      <timepoint>2 years</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Survivorship of the AVN Cage as defined by revision of the AVN Cage for any reason and analysed by Kaplan-Meier plots.</outcome>
      <timepoint>1, 2, 3, 4 and 5 years</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Skeletally mature
ARCO stage II osteonecrosis of the femoral head</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Acetabular degeneration
Had previous surgery for AVN in the affected hip
Deformity in the upper femur
Drug or alcohol abuse or condition that could affect follow-up
Pregnancy
Nickel or metal sensitivity
Local or systemic infection
Surgical treatment on contralateral hip in last 3 months or planned for within 3 months after surgery
Paget's or Charcot's disease
Osteonecrotic lesion considered to be at limited risk of progression</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>17/10/2012</anticipatedstartdate>
    <actualstartdate>6/11/2012</actualstartdate>
    <anticipatedenddate />
    <actualenddate>5/03/2014</actualenddate>
    <samplesize>77</samplesize>
    <actualsamplesize>18</actualsamplesize>
    <recruitmentstatus>Stopped early</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>20/04/2016</actuallastvisitdate>
    <dataanalysis>Data collected is being analysed</dataanalysis>
    <withdrawnreason>Participant recruitment difficulties,Other reasons/comments</withdrawnreason>
    <withdrawnreasonother>There are subtleties in the ARCO staging process that make it difficult to ascertain a patient's definite eligibility.</withdrawnreasonother>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <countryoutsideaustralia>
      <country>Hong Kong</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Thailand</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>DePuy International Ltd</primarysponsorname>
    <primarysponsoraddress>1, White Rose Office Park
Millshaw Park Lane
Leeds
LS11 0BG</primarysponsoraddress>
    <primarysponsorcountry>United Kingdom</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>DePuy International Ltd</fundingname>
      <fundingaddress>1, White Rose Office Park
Millshaw Park Lane
Leeds
LS11 0BG</fundingaddress>
      <fundingcountry>United Kingdom</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Commercial sector/Industry</sponsortype>
      <sponsorname>Johnson&amp; Johnson Medical Pty. Ltd.</sponsorname>
      <sponsoraddress>1-5 Khartoum Road
North Ryde
NSW 2113</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to determine whether the DePuy AVN Cage is a safe and effective treatment for avascular necrosis of the hip in patients for whom the disease has not yet progressed beyond a certain stage. Each surgery will be considered a success if 2 years after surgery the disease has not progressed to the next stage and if the patient has no need for further surgery on that hip.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>St Vincent's Hospital (Melbourne) Human Research Ethics Committee-D</ethicname>
      <ethicaddress>Level 6, de Lacy Building
St Vincent's Hospital,
390 Victoria Street,
Darlinghurst,
NSW 2010</ethicaddress>
      <ethicapprovaldate>21/10/2011</ethicapprovaldate>
      <hrec>1 1 9 /1 1</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Sue Kemp, Ph.D.</name>
      <address>DePuy Synthes
St. Anthonys Road
Leeds
LS11 8DT
United Kingdom
</address>
      <phone>+44 113 387 7804</phone>
      <fax />
      <email>skemp1@its.jnj.com</email>
      <country>United Kingdom</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Sue Kemp, Ph. D.</name>
      <address>DePuy Synthes
St. Anthonys Road
Leeds
LS11 8DT
United Kingdom
</address>
      <phone>+44 113 387 7804</phone>
      <fax />
      <email>skemp1@its.jnj.com</email>
      <country>United Kingdom</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Sue Kemp, Ph.D.</name>
      <address>DePuy Synthes
St. Anthonys Road
Leeds
LS11 8DT
United Kingdom
</address>
      <phone>+44 113 387 7804</phone>
      <fax />
      <email>skemp1@its.jnj.com</email>
      <country>United Kingdom</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Peter Chiu</name>
      <address>Room 216, New Clinical Building,
Queen Mary Hospital,
102 Pok Fu Lam Rd
Pokfulam,
Hong Kong</address>
      <phone>+852 (2255) 4259</phone>
      <fax />
      <email>pkychiu@netvigator.com</email>
      <country>Hong Kong</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>